(S)-( )-Ibuprofen

Research use only, not for human use.

An enantiomer of Ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form.

An enantiomer of Ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form; also inhibits activation of NF-κB more effectively than (R)-ibuprofen (IC50=62 and 122 uM, respectively).(In Vitro):(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent.(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1.(S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM.(In Vivo):(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.

(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1. (S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM. Cell Proliferation Assay Cell Line:HCT-15 and HCA-7 cells Concentration:0 μM, 200 μM, 400 μM, 600 μM, 700 μM, 800 μM, 900 μM, and 1000 μM Incubation Time:8 days Result:Reduced concentration dependently cell survival in both cell lines to a similar extent.Cell Cycle Analysis Cell Line:HCT-15 and HCA-7 cells Concentration:0 μM, 200 μM, 400 μM, 600 μM, 800 μM, 900 μM, and 1000 μM Incubation Time:24 hours (HCT-15) or 20 hours (HCA-7)Result:Caused a G0/G1 phase block.Apoptosis Analysis Cell Line:HCT-15 and HCA-7 cells Concentration:0 μM, 200 μM, 400 μM, 600 μM, 800 μM, 900 μM, and 1000 μM Incubation Time:72 hours Result:Induced cell apoptosis.Western Blot Analysis Cell Line:HCT-15 and HCA-7 cells Concentration:900 μM Incubation Time:4 hours, 8 hours, 16 hours, 24 hours, 32 hours, 48 hours and 72 hours Result:Decreased levels of Cyclin D1 protein.

(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model. Animal Model:NMRI (nu/nu) male mice (6-8 week old ) injected with HCA-7 and HCT-15 cells Dosage:15 mg/kg/day Administration:Intraperitoneal injection; five days a week; for 4 weeks Result:Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice.

S)-Ibuprofen

Chromatin/Epigenetic

COX

Bcl-2|COX|Cysticfibrosistransmembraneconductanceregulator|PPARγ|thrombomodulin

Inflammation/Immunology

——

51146-56-6

206.2808

C13H18O2

>98% (HPLC)

H2O: 1 mg/mL (Need ultrasonic and warming); DMSO: < 0.1 mg/mL

C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O

Benzeneacetic acid, α-methyl-4-(2-methylpropyl)-,(αS)-

(-20℃)

With Ice Pack

≥ 2 years